A carregar...
Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis
The combination of standard-dose chemotherapy and immunotherapy has been shown to be beneficial for patients with non-small cell lung cancer (NSCLC) with good performance status (PS). However, treatment options for patients with poor PS are limited. In the present study, the feasibility and immunolo...
Na minha lista:
| Publicado no: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6312929/ https://ncbi.nlm.nih.gov/pubmed/30655905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2018.9724 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|